Assessment of Thyroid Function in Major Thalassemia Patients above 12 Year of Age

International Journal of Medical Science

© 2017 by SSRG - IJMS Journal

Volume 4 Issue 6

Year of Publication : 2017

Authors : Dr. Jyoti Prakash Yogi, Dr. Mukesh Soni and Dr. Prakash Keshwani

10.14445/23939117/IJMS-V4I6P104

How to Cite?

Dr. Jyoti Prakash Yogi, Dr. Mukesh Soni and Dr. Prakash Keshwani, "Assessment of Thyroid Function in Major Thalassemia Patients above 12 Year of Age," SSRG International Journal of Medical Science, vol. 4,  no. 6, pp. 15-17, 2017. Crossref, https://doi.org/10.14445/23939117/IJMS-V4I6P104

Abstract:

Thyroid dysfunctions in patients with betathalassemia are the result of iron toxicity to thyroid cells. The present study was conducted in 160 subjects divided into two groups -Group A comprised of 80 diagnosed cases of β-thalassemia major above 12 years of age receiving regular blood transfusions for more than last 3 years and at least 10 transfusions in a year. Group B comprised of age and sex matched 80 healthy individuals. We found that prevalence of hypothyroidism in patients with beta-thalassemia major was 20% patients, which was significantly (p<0.0001) higher than the group B, in which prevalence of hypothyroidism was only 3.75%.

Keywords:

β-thalassemia major, Hypothyroidism.

References:

[1] Modell B, Khan M, Darlison M, King A, Layton M, Old J, Petrou M, Varnavides L, 2001: A national register for surveillance of inherited disorders: beta thalassemia in the United Kingdom. Bulletin of the WHO 79:1006-1013.
[2] Rund D, Rachmilewitz E, 2005: Beta–thalassemia. N Engl J Med 353:1135-1146.
[3] Olivieri NF, 1999: The beta-thalassemias. N Engl J Med 341:99-109.
[4] Landau H, Matoth I, Landau-Cordova Z, Goldfarb A, Rachmilewitz EA, Glaser B. (1993). Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major, ClinEndocrinol (Oxf), Vol.38 (1), pp. 55-61.
[5] Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. (2003). labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood, Vol.102 (7), pp.2670-7.
[6] Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A. (2009). Improved survival in thalassemia major patients on switching, from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica, Vol. 94(12), pp. 1777-8.
[7] Klein I, Danzi S. (2007) Thyroid disease and the heart. Circulation, vol. 116, pp. 1725.
[8] Bernal J. (2002) Action of thyroid hormone in brain, Journal of Endocrinological Investigation, Vol. 25, pp. 268–288.
[9] Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A: Survival and complications in thalassemia. Ann N Y AcadSci2005, 1054:40-47
[10] KallistheniFarmaki (2012). Hypothyroidism in Thalassemia, Hypothyroidism - Influences and Treatments, Dr. Drahomira Springer (Ed.), 5:97-110
[11] Gabutti V, Piga A: Results of long-term iron-chelating therapy. ActaHaematol1996, 95:26-36.